Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]PRNewsWire • 08/07/23
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple SclerosisPRNewsWire • 08/07/23
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 YearsThe Motley Fool • 08/04/23
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with KindevaPRNewsWire • 07/31/23
VTRS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 14, 2023 in the Class Action Filed on Behalf of Viatris Inc. ShareholdersPRNewsWire • 07/14/23
VTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023PRNewsWire • 07/14/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc. (VTRS)Business Wire • 07/13/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 14, 2023 - (NASDAQ: VTRS)PRNewsWire • 07/12/23
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRSPRNewsWire • 07/11/23